Anti-Hypertensive Drugs - Bangladesh

Bangladesh

In Bangladesh, the revenue of the Anti-Hypertensive Drugs market is estimated to reach US$14.61m by the year 2024.
It is anticipated that the revenue will exhibit an annual growth rate (CAGR 2024-2028) of 1.52%, leading to a market volume of US$15.52m by 2028.
When compared globally, United States is expected to generate the highest revenue in this market, projected to be US$12,290.00m in 2024.
The demand for anti-hypertensive drugs in Bangladesh is rising steadily due to the high prevalence of hypertension in the population.

Key regions: Germany, United States, France, China, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Hypertensive Drugs market in Bangladesh has been growing steadily over the past few years.

Customer preferences: Bangladesh has a high prevalence of hypertension, which has led to an increase in demand for anti-hypertensive drugs. Customers prefer affordable and easily accessible drugs, which has led to a rise in the production and consumption of generic drugs in the country.

Trends in the market: The market is dominated by a few major players, but there has been an increase in the number of local manufacturers of anti-hypertensive drugs. This has led to increased competition and has helped to drive down prices. The market is expected to continue to grow as the population ages and the prevalence of hypertension increases.

Local special circumstances: Bangladesh has a large population and a high burden of disease, which has led to a focus on expanding access to healthcare. The government has implemented policies to increase access to essential medicines, including anti-hypertensive drugs. This has helped to increase demand for these drugs in the country.

Underlying macroeconomic factors: Bangladesh has experienced steady economic growth over the past few years, which has led to an increase in healthcare spending. The government has also increased its investment in the healthcare sector, which has helped to improve access to healthcare services and medicines. However, the country still faces challenges in terms of healthcare infrastructure and human resources, which may limit the growth of the anti-hypertensive drugs market in the long term.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.